← Leaderboards
David L Kleinberg
New York University School Of Medicine
$2,205,700
Attributed
$2,205,700
Total exposure
13
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $333.6K · FY2005–06$500K$375K$250K$125K$0
'05
'06
Funding mix
By agency
NIH$2,205,700 · 13
By mechanism
R01$2,004,320 · 1
M01$201,380 · 12
Top collaborators
No co-investigators on record.
Most similar at New York University School Of Medicine
Same institution · by research overlap
- Iannis Aifantis$31,581,069
Others in their field
Top investigators on “Somatotropin”
- Brian E Henderson · University Of Southern California$17,806,295
- Johannes D Veldhuis · University Of Virginia Charlottesville$14,094,397
- Dan M Cooper · University Of California San Diego$13,278,892
- Stanley B Prusiner · University Of California San Francisco$12,108,025
- Steven Kyle Grinspoon · Massachusetts General Hospital$11,432,307
- David J Waxman · Boston University Medical Campus$10,042,015
Research focus
SomatotropinHuman SubjectClinical ResearchInsulinlike Growth FactorHuman Therapy EvaluationAcromegalyDrug Screening /EvaluationEndocrine Disorder ChemotherapyHormone TherapySomatostatinPeptide Hormone AnalogDrug Adverse EffectSkeletal Disorder ChemotherapyHormone Regulation /Control MechanismPituitary DwarfismNeoplasm /Cancer ChemotherapyHormone ReceptorPolyethylene GlycolsHormone InhibitorLaboratory MouseCarcinogenesisBreast NeoplasmsIn Situ HybridizationFemale
Grant awards (45)
Mammary Carcinogenesis: Growth Hormone and IGF-I$316,855
R01 · FY2006 · CA · contact PI
SURGICAL DEBULKING PLUS OCTREOTIDE VERSUS OCTREOTIDE ALONE IN ACROMEGALY$6,079
M01 · FY2006 · RR · contact PI
PREVALENCE OF GROWTH HORMONE DEFICIENCY & RANGES OF IGF-1 IN NORMAL ELDERLY$4,209
M01 · FY2006 · RR · contact PI
Mammary Carcinogenesis: Growth Hormone and IGF-I$324,480
R01 · FY2005 · CA
PREVALENCE OF GROWTH HORMONE DEFICIENCY &RANGES OF IGF-1 IN NORMAL ELDERLY$9,071
M01 · FY2005 · RR
Mammary Carcinogenesis: Growth Hormone and IGF-I$324,480
R01 · FY2004 · CA
Prevalence of Growth Hormone Deficiency &Ranges of IGF-1 in Normal Elderly$13,973
M01 · FY2004 · RR
Mammary Carcinogenesis: Growth Hormone and IGF-I$323,840
R01 · FY2003 · CA
Mammary Carcinogenesis: Growth Hormone and IGF-I$322,880
R01 · FY2002 · CA
NEW APPROACHES TO THE EARLY DIAGNOSIS/DETECTION OF RECURRENCE OF ACROMEGALY$0
M01 · FY2002 · RR
SANDOSTATIN LAR IN PATIENTS W/ ACROMEGALY$0
M01 · FY2002 · RR
B2036 PEG IN ACROMEGALY$0
M01 · FY2002 · RR
LONG TERM SAFETY &EFFICACY OF LANREOTIDE FOR TREATMENT OF ACROMEGALICS$0
M01 · FY2002 · RR
SAFETY &EFFICACY OF LANREOTIDE (IPSTYL) IN ACROMEGALICS$0
M01 · FY2002 · RR
LANREOTIDE (IPSTYL) IN " DENOVO" ACROMEGALICS$0
M01 · FY2002 · RR
HYPOPITUITARY CONTROL AND COMPLICATIONS$0
M01 · FY2002 · RR
EFFECT OF RHGH ON ENDURANCE AND CARDIOPULMONARY FUNCTION IN GH DEFICIENT ADULTS$0
M01 · FY2002 · RR
MAMMARY CARCINOGENESIS--GROWTH HORMONE AND IGF-I$74,252
R01 · FY2001 · CA
LANREOTIDE (IPSTYL) IN " DENOVO" ACROMEGALICS$0
M01 · FY2001 · RR
NEW APPROACHES TO THE EARLY DIAGNOSIS/DETECTION OF RECURRENCE OF ACROMEGALY$0
M01 · FY2001 · RR
EFFECT OF RHGH ON ENDURANCE AND CARDIOPULMONARY FUNCTION IN GH DEFICIENT ADULTS$0
M01 · FY2001 · RR
HYPOPITUITARY CONTROL AND COMPLICATIONS$0
M01 · FY2001 · RR
SAFETY &EFFICACY OF LANREOTIDE (IPSTYL) IN ACROMEGALICS$0
M01 · FY2001 · RR
LONG TERM SAFETY &EFFICACY OF LANREOTIDE FOR TREATMENT OF ACROMEGALICS$0
M01 · FY2001 · RR
B2036 PEG IN ACROMEGALY$0
M01 · FY2001 · RR
SANDOSTATIN LAR IN PATIENTS W/ ACROMEGALY$0
M01 · FY2001 · RR
MAMMARY CARCINOGENESIS--GROWTH HORMONE AND IGF-I$317,533
R01 · FY2000 · CA
LANREOTIDE (IPSTYL) IN " DENOVO" ACROMEGALICS$21,006
M01 · FY2000 · RR
B2036 PEG IN ACROMEGALY$21,006
M01 · FY2000 · RR
HYPOPITUITARY CONTROL AND COMPLICATIONS$21,006
M01 · FY2000 · RR
LONG TERM SAFETY &EFFICACY OF LANREOTIDE FOR TREATMENT OF ACROMEGALICS$21,006
M01 · FY2000 · RR
SANDOSTATIN LAR IN PATIENTS W/ ACROMEGALY$21,006
M01 · FY2000 · RR
EFFECT OF RHGH ON ENDURANCE AND CARDIOPULMONARY FUNCTION IN GH DEFICIENT ADULTS$21,006
M01 · FY2000 · RR
SAFETY &EFFICACY OF LANREOTIDE (IPSTYL) IN ACROMEGALICS$21,006
M01 · FY2000 · RR
NEW APPROACHES TO THE EARLY DIAGNOSIS/DETECTION OF RECURRENCE OF ACROMEGALY$21,006
M01 · FY2000 · RR
HYPOPITUITARY CONTROL AND COMPLICATIONS$0
M01 · FY2000 · RR
EFFECT OF RHGH ON ENDURANCE AND CARDIOPULMONARY FUNCTION IN GH DEFICIENT ADULTS$0
M01 · FY2000 · RR
B2036 PEG IN ACROMEGALY TREATMENT$0
M01 · FY2000 · RR
B2036 PEG IN ACROMEGALY TREATMENT$0
M01 · FY2000 · RR
SANDOSTATIN LAR IN PATIENTS W/ ACROMEGALY$0
M01 · FY2000 · RR
B2036 PEG IN ACROMEGALY$0
M01 · FY2000 · RR
LONG TERM SAFETY &EFFICACY OF LANREOTIDE FOR TREATMENT OF ACROMEGALICS$0
M01 · FY2000 · RR
SAFETY &EFFICACY OF LANREOTIDE (IPSTYL) IN ACROMEGALICS$0
M01 · FY2000 · RR
LANREOTIDE (IPSTYL) IN " DENOVO" ACROMEGALICS$0
M01 · FY2000 · RR
NEW APPROACHES TO THE EARLY DIAGNOSIS/DETECTION OF RECURRENCE OF ACROMEGALY$0
M01 · FY2000 · RR